
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1561624
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study isolated a Klebsiella pasteurii strain, K1134, from the sputum of an ICU patient, revealing its resistance to the carbapenem antibiotics meropenem and imipenem. Whole-genome sequencing identified a plasmid pK1134-KPC, which carries the carbapenem resistance gene blaKPC-2. pK1134-KPC, belonging to the IncFIIpCP020359 plasmid group, exhibits a modular structure with blaKPC-2 embedded in a 32.09 kb accessory region containing multiple accessory genetic elements (AGEs). Comparative genomic analysis of 48 K. pasteurii isolates from 12 countries showed high genetic diversity, with strains clustered into three clades. Notably, K. pasteurii harbors extensive antimicrobial resistance genes across diverse AGEs, classifying it as multidrug-resistant. 12 blaKPC-carrying AGEs were identified from the sequences of the isolates, classified into two groups: Tn7551 and Tn6296-related elements. The gene clusters for enterotoxins tilimycin and tilivalline, encompassing key regulators and operons, were present in nearly all strains, with incomplete clusters exclusively observed in Clade 3 isolates. This study underscores the global dissemination and genetic adaptability of K. pasteurii, highlighting its potential role as a reservoir for resistance genes and emphasizing the need for robust surveillance to mitigate its public health impact.
Keywords: Klebsiella pasteurii, Carbapenem resistance, Plasmid, blaKPC, mobile genetic element, tilimycin and tilivalline
Received: 16 Jan 2025; Accepted: 03 Mar 2025.
Copyright: © 2025 Li, Song, Liu, Jin, Wan, Chen and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xinhua Luo, Department of Clinical Laboratory Medicine, Taizhou Municipal Hospital, Taizhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.